ScoreWhy is Sarepta Therapeutics, Inc. ?
1
Negative results in Jun 26
- INTEREST(HY) At USD 43.22 MM has Grown at 344.16%
- NET SALES(Q) At USD 401.25 MM has Fallen at -34.34%
- PRE-TAX PROFIT(Q) At USD 37.7 MM has Fallen at -67.76%
2
Risky -
- The stock is trading risky as compared to its average historical valuations
- Over the past year, while the stock has generated a return of -6.57%, its profits have fallen by -372.1%
3
Below par performance in long term as well as near term
- Along with generating -6.57% returns in the last 1 year, the stock has also underperformed S&P 500 in the last 3 years, 1 year and 3 months
Real-Time Research ReportHow much should you sell?
- All quantity irrespective of whether you are making profits or losses
(If sector exposure > 30%, please use optimiser tool to see which are the best stocks to hold in Pharmaceuticals & Biotechnology)
When to re-enter? - We will constantly monitor the company and review our call based on new data
Is Sarepta Therapeutics, Inc. for you?
High Risk, Low Return
Absolute
Risk Adjusted
Volatility
Sarepta Therapeutics, Inc.
-5.76%
-1.05
82.45%
S&P 500
21.34%
1.69
13.20%
Quality
Management Risk
Growth
Capital StructureQuality key factors
Factor
Value
Sales Growth (5y)
32.41%
EBIT Growth (5y)
-3.57%
EBIT to Interest (avg)
-8.03
Debt to EBITDA (avg)
Negative Net Debt
Net Debt to Equity (avg)
0.54
Sales to Capital Employed (avg)
0.79
Tax Ratio
51.28%
Dividend Payout Ratio
0
Pledged Shares
0
Institutional Holding
100.00%
ROCE (avg)
0
ROE (avg)
1.18%
ValuationValuation Key Factors 
Factor
Value
P/E Ratio
NA (Loss Making)
Industry P/E
Price to Book Value
1.84
EV to EBIT
-3.04
EV to EBITDA
-3.36
EV to Capital Employed
1.92
EV to Sales
0.91
PEG Ratio
NA
Dividend Yield
NA
ROCE (Latest)
-63.18%
ROE (Latest)
-57.69%
TechnicalsTechnical key factors
Indicator
Weekly
Monthly
MACD
Mildly Bullish
Mildly Bullish
RSI
No Signal
Bullish
Bollinger Bands
Bullish
Bearish
Moving Averages
Mildly Bearish (Daily)
KST
Mildly Bullish
Bearish
Dow Theory
Mildly Bullish
No Trend
OBV
Mildly Bullish
Mildly Bullish
Technical Indicator Scale: Bearish, Mildly Bearish, Sideways, Mildly Bullish, Bullish Turned 
Financial Trend10What is working for the Company
OPERATING CASH FLOW(Y)
Highest at USD 93.95 MM
NET PROFIT(HY)
Higher at USD 367.17 MM
-23What is not working for the Company
INTEREST(HY)
At USD 43.22 MM has Grown at 344.16%
NET SALES(Q)
At USD 401.25 MM has Fallen at -34.34%
PRE-TAX PROFIT(Q)
At USD 37.7 MM has Fallen at -67.76%
NET PROFIT(Q)
At USD 34.56 MM has Fallen at -78.42%
RAW MATERIAL COST(Y)
Grown by 18.1% (YoY
Here's what is working for Sarepta Therapeutics, Inc.
Operating Cash Flow
Highest at USD 93.95 MM and Grown
In each year in the last three yearsMOJO Watch
The company has generated higher cash revenues from business operations
Operating Cash Flows (USD MM)
Here's what is not working for Sarepta Therapeutics, Inc.
Interest
At USD 43.22 MM has Grown at 344.16%
over previous Semi-Annual periodMOJO Watch
Rising interest cost signifies increased borrowings
Interest Paid (USD MM)
Net Sales
At USD 401.25 MM has Fallen at -34.34%
Year on Year (YoY)MOJO Watch
Near term sales trend is extremely negative
Net Sales (USD MM)
Pre-Tax Profit
At USD 37.7 MM has Fallen at -67.76%
Year on Year (YoY)MOJO Watch
Near term Pre-Tax Profit trend is very negative
Pre-Tax Profit (USD MM)
Net Profit
At USD 34.56 MM has Fallen at -78.42%
Year on Year (YoY)MOJO Watch
Near term Net Profit trend is very negative
Net Profit (USD MM)
Raw Material Cost
Grown by 18.1% (YoY)
MOJO Watch
The company's ability to pass on the cost of raw materials to customers has deteriorated; this may lead to a fall in profit margin
Raw Material Cost as a percentage of Sales
InfinHub Market Technologies FZ-LLC, Building-2, Unit 112, Dubai Internet City, Dubai, United Arab Emirates
GET THE MARKETSMOJO APP
Company
Stocks
Portfolio
"Investment in securities markets are subject to market risk. Read all the related documents carefully before investing."
